George Sosenko, MD
Urology · Downers Grove, ILNPI 1881680411
Payments from drug & device makers
Across 308 payments — averaging $31.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gyrus ACMI, Inc.$2K
- Antares Pharma, Inc.$1K
- AbbVie$791
- Astellas Pharma US Inc$758
- Medivators Inc.$500
- Teleflex LLC$478
- plus $4K from 30 others
What the payments were for
- Consulting fees$1,80019%
- Speaking & faculty fees$5145%
- Food & beverage$6,68770%
- Education$5225%
- Other$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gyrus ACMI, Inc. | 1 | $1,800 |
| Antares Pharma, Inc. | 73 | $1,242 |
| AbbVie(2 entities) | 37 | $791 |
| Astellas Pharma US Inc | 20 | $758 |
| Medivators Inc. | 1 | $500 |
| Teleflex LLC | 18 | $478 |
| Pfizer | 25 | $455 |
| AstraZeneca | 3 | $311 |
| Medtronic | 10 | $289 |
| Johnson & Johnson | 9 | $280 |
| Bayer | 14 | $267 |
| Myovant Sciences Inc. | 9 | $262 |
| Urovant Sciences Inc | 13 | $261 |
| Boston Scientific | 9 | $247 |
| Sumitomo Pharma America, Inc. | 9 | $241 |
| Olympus America Inc. | 6 | $235 |
| Halozyme Inc | 14 | $183 |
| Metuchen Pharmaceuticals | 1 | $171 |
| Neotract Inc. | 3 | $118 |
| Procept Biorobotics Corporation | 2 | $91 |
| Axonics, Inc. | 5 | $87 |
| 180 Medical, Inc. | 3 | $76 |
| Tolmar, Inc. | 4 | $75 |
| Myriad Genetic Laboratories, Inc. | 3 | $59 |
| Clarus Therapeutics Inc. | 3 | $50 |
| Novartis | 2 | $45 |
| Kerecis Limited | 1 | $43 |
| Blue Earth Diagnostics | 2 | $33 |
| Laborie Medical Technologies Corp. | 1 | $29 |
| Agiliti Surgical, Inc. | 1 | $26 |
| Profound Medical Corp. | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| KARL Storz Endoscopy-america | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,603 in reported general payments places this provider in the 80th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $206,681 |
| MyrbetriqMirabegron | 152 | $145,052 |
| OrgovyxRelugolix | 53 | $139,938 |
| GemtesaVibegron | 57 | $53,923 |
| Tamsulosin Hcl | 1,166 | $16,090 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 641 | $12,547 |
| XyostedTestosterone Enanthate | 15 | $9,376 |
| Solifenacin Succinate | 166 | $6,954 |
| Oxybutynin Chloride ErOxybutynin Chloride | 258 | $6,552 |
| Finasteride | 406 | $5,511 |
| Methenamine Hippurate | 42 | $4,317 |
| Testosterone | 20 | $2,893 |
| Bicalutamide | 70 | $2,299 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,518 |
| Silodosin | 15 | $1,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $758 | $351,733166 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $241 | $193,861110 claims |
| Antares Pharma, Inc.Xyosted | $1,242 | $9,37615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 550 urology providers in Illinois.
Other urology in Downers Grove
- Mark BrandtPark Ridge$3M
- Ashley RossChicago$2.3M
- Aaron BergerChicago Ridge$2.1M
- Joshua MeeksChicago$2M
- Courtney HollowellChicago$1.9M
- David LieberSpringfield$1.5M
- Gary SteinbergChicago$1.4M
- Brian HelfandChicago$1.2M
- Simone CrivellaroChicago$1.1M
- Michael AbernChicago$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.